search
Back to results

Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers

Primary Purpose

Alcohol Use Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Brief intervention
Sponsored by
New York State Psychiatric Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Alcohol Use Disorder focused on measuring brief intervention, fMRI

Eligibility Criteria

21 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria (Problem Drinkers):

  • Age 21-55
  • English language fluency
  • Over the last 28 days ,Have an average weekly consumption of greater than 14 standard drinks for women, and greater than 24 standard drinks for men.
  • Current DSM-V mild or moderate alcohol use disorder (AUD) diagnosis
  • Own a smartphone with data plan

Inclusion Criteria (Healthy Controls):

  • Age 21-55
  • English language fluency
  • Have an average weekly consumption of less than </=14 standard drinks for women and less than/equal to 24 standard drinks for men and up to 2 heavy drinking days (>4/5 standard drinks for a woman/man)
  • No lifetime diagnosis of AUD
  • owns smartphone with a data plan

Exclusion Criteria:

  • Past or current severe AUD as defined by DSM- V
  • Currently seeking treatment or attempting to stop drinking
  • Past or current alcohol withdrawal symptoms
  • Current DSM-V diagnosis of substance use disorder (other than nicotine or caffeine).
  • Regular use (more than 1-2 times weekly) of recreational drugs.
  • Psychotic Disorder or Bipolar disorder
  • Severe depression (Patient Health Questionnaire score > 19) or anxiety (Beck Anxiety Inventory > 25)
  • Substantial risk of suicide or violence
  • MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist > 55")
  • Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective
  • Objective cognitive impairment
  • Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma. - Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II). Well-treated hypothyroidism will not be excluded.
  • Pregnant, lactating (participation allowed 3 months after ceasing lactation), or currently intending to become pregnant
  • Any history of ECT
  • Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury (LOC > 5 minutes), mental retardation
  • Diagnosed learning disability, dyslexia, or ADHD
  • For women: Current pregnancy or intention to be pregnant in the near future

Sites / Locations

  • NYPInstitute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Brief Intervention

Delayed Intervention

Arm Description

Participants will receive a brief intervention at week 0

Participants will receive a brief intervention at 6 months

Outcomes

Primary Outcome Measures

Drinking
Heavy drinking days

Secondary Outcome Measures

Full Information

First Posted
March 1, 2018
Last Updated
July 3, 2023
Sponsor
New York State Psychiatric Institute
Collaborators
Northwell Health
search

1. Study Identification

Unique Protocol Identification Number
NCT03457077
Brief Title
Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers
Official Title
Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
February 27, 2018 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
New York State Psychiatric Institute
Collaborators
Northwell Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will examine the neural mechanisms underlying both spontaneous behavior change and behavior change in response to a brief intervention among problem drinkers.
Detailed Description
Although problem drinkers (PD) are a less severe, highly prevalent sub-type of alcohol use disorder (AUD) who are more likely to undergo reductions in alcohol use, compared to more severe AUD, the underlying mechanisms that maintain PD, as well as the mechanisms that underlie both spontaneous and treatment- related behavior change in this population, are not well understood. This proposal takes a lab to life approach by combining functional neuroimaging (fMRI), ecological momentary assessment (EMA), and brief interventions (BI) in non-treatment seeking PD to test whether heightened incentive salience (reactivity) to alcohol cues and impaired ability to regulate cue-induce craving are the mechanisms that characterize PD, and play a role in behavior change vs. persistence of behavior. Identifying these mechanisms is critical for testing and understanding treatments and uncovering who is most likely to respond to interventions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder
Keywords
brief intervention, fMRI

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
164 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Brief Intervention
Arm Type
Experimental
Arm Description
Participants will receive a brief intervention at week 0
Arm Title
Delayed Intervention
Arm Type
Other
Arm Description
Participants will receive a brief intervention at 6 months
Intervention Type
Behavioral
Intervention Name(s)
Brief intervention
Intervention Description
A brief motivational intervention with feedback about drinking levels compared to norms
Primary Outcome Measure Information:
Title
Drinking
Description
Heavy drinking days
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (Problem Drinkers): Age 21-55 English language fluency Over the last 28 days ,Have an average weekly consumption of greater than 14 standard drinks for women, and greater than 24 standard drinks for men. Current DSM-V mild or moderate alcohol use disorder (AUD) diagnosis Own a smartphone with data plan Inclusion Criteria (Healthy Controls): Age 21-55 English language fluency Have an average weekly consumption of less than </=14 standard drinks for women and less than/equal to 24 standard drinks for men and up to 2 heavy drinking days (>4/5 standard drinks for a woman/man) No lifetime diagnosis of AUD owns smartphone with a data plan Exclusion Criteria: Past or current severe AUD as defined by DSM- V Currently seeking treatment or attempting to stop drinking Past or current alcohol withdrawal symptoms Current DSM-V diagnosis of substance use disorder (other than nicotine or caffeine). Regular use (more than 1-2 times weekly) of recreational drugs. Psychotic Disorder or Bipolar disorder Severe depression (Patient Health Questionnaire score > 19) or anxiety (Beck Anxiety Inventory > 25) Substantial risk of suicide or violence MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist > 55") Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective Objective cognitive impairment Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma. - Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II). Well-treated hypothyroidism will not be excluded. Pregnant, lactating (participation allowed 3 months after ceasing lactation), or currently intending to become pregnant Any history of ECT Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury (LOC > 5 minutes), mental retardation Diagnosed learning disability, dyslexia, or ADHD For women: Current pregnancy or intention to be pregnant in the near future
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nasir Naqvi, MD, PhD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYPInstitute
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers

We'll reach out to this number within 24 hrs